|
1
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49.
2024.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Xu L, Cheng Z, Cui C, Wu X, Yu H, Guo J
and Kong Y: Frequent genetic aberrations in the cell cycle related
genes in mucosal melanoma indicate the potential for targeted
therapy. J Transl Med. 17(245)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kozovska Z, Gabrisova V and Kucerova L:
Malignant melanoma: Diagnosis, treatment and cancer stem cells.
Neoplasma. 63:510–517. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Luke JJ, Flaherty KT, Ribas A and Long GV:
Targeted agents and immunotherapies: Optimizing outcomes in
melanoma. Nat Rev Clin Oncol. 14:463–482. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Herndon TM, Demko SG, Jiang X, He K,
Gootenberg JE, Cohen MH, Keegan P and Pazdur R: U.S. Food and drug
administration approval: Peginterferon-alfa-2b for the adjuvant
treatment of patients with melanoma. Oncologist. 17:1323–1328.
2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Slominski A, Tobin DJ, Shibahara S and
Wortsman J: Melanin pigmentation in mammalian skin and its hormonal
regulation. Physiol Rev. 84:1155–1228. 2004.PubMed/NCBI View Article : Google Scholar
|
|
7
|
dos Santos Videira IF, Moura DF and Magina
S: Mechanisms regulating melanogenesis. An Bras Dermatol. 88:76–83.
2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Garmyn M, Young AR and Miller SA:
Mechanisms of and variables affecting UVR photoadaptation in human
skin. Photochem Photobiol Sci. 17:1932–1940. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Slominski RM, Sarna T, Plonka PM, Raman C,
Brozyna AA and Slominski AT: Melanoma, melanin, and melanogenesis:
The Yin and Yang relationship. Front Oncol.
12(842496)2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Slominski AT, Zmijewski MA, Plonka PM,
Szaflarski JP and Paus R: How UV light touches the brain and
endocrine system through skin, and why. Endocrinology.
159:1992–2007. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Badal B, Solovyov A, Di Cecilia S, Chan
JM, Chang LW, Iqbal R, Aydin IT, Rajan GS, Chen C, Abbate F, et al:
Transcriptional dissection of melanoma identifies a high-risk
subtype underlying TP53 family genes and epigenome deregulation.
JCI Insight. 2(e92102)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kanehisa M and Goto S: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ashburner M, Ball CA, Blake JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: tool for the unification of biology. The gene
ontology consortium. Nat Genet. 25:25–29. 2000.PubMed/NCBI View
Article : Google Scholar
|
|
14
|
Talantov D, Mazumder A, Yu JX, Briggs T,
Jiang Y, Backus J, Atkins D and Wang Y: Novel genes associated with
malignant melanoma but not benign melanocytic lesions. Clin Cancer
Res. 11:7234–7242. 2005.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kabbarah O, Nogueira C, Feng B, Nazarian
RM, Bosenberg M, Wu M, Scott KL, Kwong LN, Xiao Y, Cordon-Cardo C,
et al: Integrative genome comparison of primary and metastatic
melanomas. PLoS One. 5(e10770)2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zavaleta-Monestel E, Quesada-Villaseñor R,
Barrantes-López M, Arguedas-Chacón S, Campos-Hernández J,
Rojas-Chinchilla C, García-Montero J, Castro-Ulloa J, Anchía-Alfaro
A and Montenegro-Chaves JR: Advancements in the treatment of
multiple myeloma. Cureus. 16(e74970)2024.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Jitian Mihulecea CR and Rotaru M: Review:
The key factors to melanomagenesis. Life (Basel).
13(181)2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Aguirre-Portoles C, Bird AW, Hyman A,
Canamero M, Perez de Castro I and Malumbres M: Tpx2 controls
spindle integrity, genome stability, and tumor development. Cancer
Res. 72:1518–1528. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang S, You X, Zheng Y, Shen Y, Xiong X
and Sun Y: The UBE2C/CDH1/DEPTOR axis is an oncogene and tumor
suppressor cascade in lung cancer cells. J Clin Invest.
133(e162434)2023.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wang S, Xiong Y, Luo Y, Shen Y, Zhang F,
Lan H, Pang Y, Wang X, Li X, Zheng X, et al: Genome-wide CRISPR
screens identify PKMYT1 as a therapeutic target in pancreatic
ductal adenocarcinoma. EMBO Mol Med. 16:1115–1142. 2024.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wang Y, Wang H, Yan Z, Li G, Hu G, Zhang
H, Huang D, Wang Y, Zhang X, Yan Y, et al: The critical role of
dysregulated Hh-FOXM1-TPX2 signaling in human hepatocellular
carcinoma cell proliferation. Cell Commun Signal.
18(116)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Marugán C, Sanz-Gómez N, Ortigosa B,
Monfort-Vengut A, Bertinetti C, Teijo A, González M, Alonso de la
Vega A, Lallena MJ, Moreno-Bueno G and de Cárcer G: TPX2
overexpression promotes sensitivity to dasatinib in breast cancer
by activating YAP transcriptional signaling. Mol Oncol.
18:1531–1551. 2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Jiang G, Li RH, Sun C, Liu YQ and Zheng
JN: Dacarbazine combined targeted therapy versus dacarbazine alone
in patients with malignant melanoma: a meta-analysis. PLoS One.
9(e111920)2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Middleton MR, Grob JJ, Aaronson N,
Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates
A, et al: Randomized phase III study of temozolomide versus
dacarbazine in the treatment of patients with advanced metastatic
malignant melanoma. J Clin Oncol. 18:158–166. 2000.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Guven K, Kittler H, Wolff K and
Pehamberger H: Cisplatin and carboplatin combination as second-line
chemotherapy in dacarbazine-resistant melanoma patients. Melanoma
Res. 11:411–415. 2001.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Larkin J, Del Vecchio M, Mandalá M, Gogas
H, Arance Fernandez AM, Dalle S, Cowey CL, Schenker M, Grob JJ,
Chiarion-Sileni V, et al: Adjuvant nivolumab versus ipilimumab in
resected stage III/IV melanoma: 5-year efficacy and biomarker
results from CheckMate 238. Clin Cancer Res. 29:3352–3361.
2023.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Eggermont AMM, Blank CU, Mandala M, Long
GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A,
Carlino MS, et al: Adjuvant pembrolizumab versus placebo in
resected stage III melanoma. N Engl J Med. 378:1789–1801.
2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Eggermont AM, Suciu S, Santinami M,
Testori A, Kruit WH, Marsden J, Punt CJ, Salès F, Gore M, MacKie R,
et al: Adjuvant therapy with pegylated interferon alfa-2b versus
observation alone in resected stage III melanoma: Final results of
EORTC 18991, a randomised phase III trial. Lancet. 372:117–126.
2008.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J,
Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al: An
immunogenic personal neoantigen vaccine for patients with melanoma.
Nature. 547:217–221. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Holder J, Miles JA, Batchelor M, Popple H,
Walko M, Yeung W, Kannan N, Wilson AJ, Bayliss R and Gergely F:
CEP192 localises mitotic Aurora-A activity by priming its
interaction with TPX2. EMBO J. 43:5381–5420. 2024.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Li H, Wang Y, Lin K, Venkadakrishnan VB,
Bakht M, Shi W, Meng C, Zhang J, Tremble K, Liang X, et al: CHD1
promotes sensitivity to aurora kinase inhibitors by suppressing
interaction of AURKA with its coactivator TPX2. Cancer Res.
82:3088–3101. 2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bayliss R, Sardon T, Vernos I and Conti E:
Structural basis of Aurora-A activation by TPX2 at the mitotic
spindle. Mol Cell. 12:851–862. 2003.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Eyers PA, Erikson E, Chen LG and Maller
JL: A novel mechanism for activation of the protein kinase Aurora
A. Curr Biol. 13:691–697. 2003.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Shen HM, Zhang D, Xiao P, Qu B and Sun YF:
E2F1-mediated KDM4A-AS1 up-regulation promotes EMT of
hepatocellular carcinoma cells by recruiting ILF3 to stabilize
AURKA mRNA. Cancer Gene Ther. 30:1007–1017. 2023.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Polverino F, Mastrangelo A and
Guarguaglini G: Contribution of AurkA/TPX2 overexpression to
chromosomal imbalances and cancer. Cells. 13(1397)2024.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Liu S, Cai J, Qian X, Zhang J, Zhang Y,
Meng X, Wang M, Gao P and Zhong X: TPX2 lactylation is required for
the cell cycle regulation and hepatocellular carcinoma progression.
Life Sci Alliance. 8(e202402978)2025.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Vats P, Saini C, Baweja B, Srivastava SK,
Kumar A, Kushwah AS and Nema R: Aurora kinases signaling in cancer:
From molecular perception to targeted therapies. Mol Cancer.
24(180)2025.PubMed/NCBI View Article : Google Scholar
|
